Not a fan. While the reasoning behind the acquisition may be sound, I want to see our SP appreciate before we worry about acquiring more IP. A CR at this point in our journey is not ideal IMHO. I would like to see better capital management from our board.
Dont get me wrong, still very positive about our IP, and very happy to be proven wrong, however given how the company we are acquiring this from is going I don't see the need to acquire this urgently. I would much rather see us licence out our own IP, see the company re-valued, and then think about more bolt-on acquisitions. This isn't the first time I've been unimpressed with the timing of raises.
Ann: Imugene Licenses Allogeneic CD19 CAR T Cell Therapy, page-49
-
- There are more pages in this discussion • 458 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |